Now scientists want to recruit up to 10,260 people across the country for phases II and III, which involve vastly increasing the number of volunteers and expanding the age range to include older adults and children.
Saul Faust, professor of paediatric immunology and infectious diseases at the University of Southampton, which is also working on the trials, said: "We would now very much like to invite people from the Southampton area whose work brings them into possible contact with Covid patients or who are healthy and in the older age groups to take part in the next stage of trials of this Oxford Covid vaccine".
Likewise, Friday's report about a similar vaccine being developed by China's CanSino Biologics couldn't address how protective the shot might be.More news: 'We’re not closing our country' if hit by second coronavirus wave
Known as hyperimmune globulin, those products are "where the first real treatments are going to be", he said, predicting success also with research into monoclonal antibodies that home in on and neutralize the ability of the virus to enter human cells. To avoid that problem, the Oxford vaccine uses an adenovirus that normally infects chimpanzees.
Researchers have started recruiting in the next phase of human trials for the COVID-19 vaccine.
It is hoped that will give more information as to whether the vaccine can provide protection for the wider population.
Coronavirus (Covid-19) vaccine: The United States will pump up to $1.2 billion into developing AstraZeneca's potential COVID-19 vaccine and said on Thursday it would order 300 million doses, as the White House seeks solutions to the coronavirus pandemic.More news: China may pass bill to crack down on Hong Kong opposition
It said that testing would also include a paediatric trial and that it was engaging with global bodies, including the World Health Organization, for the fair allocation and distribution of the potential vaccine around the world. NIAID is helping fund trials of Moderna's vaccine candidate. Numerous candidates work in different ways, and are made with different technologies, increasing the odds that at least one approach might succeed.
At least half a dozen drugmakers have started clinical trials of their vaccines in the past two months, including Moderna Inc and Inovio Pharmaceuticals.
Meanwhile, companies and governments are beginning to scale up production now, aiming for hundreds of millions of doses of the candidates they think might win the vaccine race.More news: Google, Apple, release joint coronavirus tracking technology